QUOTE AND NEWS
Forbes  Aug 11  Comment 
Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in HanesBrands Inc (NYSE: HBI), where a total volume of 20,846 contracts has been traded thus far today, a contract volume which is...
Motley Fool  Aug 10  Comment 
The biotech heavyweight's earnings rose yet again solely because of strong Eylea sales, but there's potential for new drugs to hit the market soon that could help to carry the growth torch.
Motley Fool  Aug 5  Comment 
The potential launch of new drugs has investors thinking sales growth is on tap.
newratings.com  Aug 4  Comment 
WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals (REGN) revealed a profit for its second quarter that increased from last year. The company said its bottom line totaled $329.12 million, or $2.82 per share. This was higher than $265.47 million,...
Benzinga  Aug 3  Comment 
Shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) are down more than 19.5 percent year-to-date, but have recuperated almost 32 percent since their late-June lows. It seems like the Vetr crowd believes the rally will continue, as evidenced by...
Forbes  Aug 3  Comment 
Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in First Solar Inc (NASD: FSLR), where a total of 15,629 contracts have traded so far, representing approximately 1.6 million underlying shares....
newratings.com  Aug 1  Comment 
PARIS (dpa-AFX) - Sanofi (SNYNF, SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced the European Medicines Agency has accepted for review the Marketing Authorisation Application for sarilumab, an investigational human monoclonal antibody...
Motley Fool  Jul 29  Comment 
Both are top healthcare stocks with strong pipelines.




RELATED WIKI ARTICLES
 
TOP CONTRIBUTORS

Since its inception in 1988, Regeneron Pharmaceuticals, Inc. (REGN) has operated as a research and development (R&D) company engaged in the development of drugs for the treatment of various diseases. Regeneron's goal is to become a fully integrated biopharmaceutical company by commercializing these drugs. The company has advanced a few of its pipeline drugs into clinical stage development. The leading drug programs in this regard are IL-1, for inflamatory disease, and VEGF, for cancer and eye diseases. Revenues consist of R&D collaboration payments from development partner Sanofi-Aventis and contract manufacturing payments from pharmaceutical giant Merck for a pediatric vaccine. Manufacturing agreement expired in October 2006. From 2007, revenue will mainly derive from collaboration with Sanofi-Aventis and Bayer and from technology transfers.

Regeneron is cururently based in Tarrytown, NY. In December 2006, the company signed a 15-year lease with BioMed Realty Trust, Inc. for a new corporate headquarters and research and development complex to be constructed adjacent to its current facility at the Landmark at Eastview in the Town of Greenburgh in Westchester County, New York. Regeneron also has the option to extend the lease for three additional 5-year periods. The new facilities will be constructed by BioMed Realty Trust over the next two years.

The Platform Techonology

Regeneron's most important propriatary technology is Trap Technology utilizing engineered antibody techniques. The decoy receptors (Traps) are composed of fusions between two distinct receptor components and a portion of an antibody molecule called the "Fc region", resulting in the generation of blockers with markedly increased affinity over that offered by single component reagents. Regeneron has applied this proprietary Trap technology to create a number of therapeutic candidates such as the IL-1 Trap and the VEGF Trap. The company also developed Velocigene/VelocImmune Technology which allows custom and precise manipulation of very large sequences of DNA to produce a highly customized knock-out of a specified target gene and accelerates the production of knock-out and transgenic expression models without using either positive/negative selection or isogenic DNA.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki